Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Graft Polymer (UK) PLC ( (GB:SVNS) ) has shared an announcement.
Solvonis Therapeutics plc has announced the posting of its 2025 Annual General Meeting notice and proxy form to shareholders, with the meeting scheduled for 27 June 2025 in London. This announcement underscores Solvonis’s ongoing commitment to transparency and shareholder engagement as it progresses its clinical programs, which include a Phase 3 trial for severe Alcohol Use Disorder and a preclinical PTSD program. The company’s strategic focus on high-burden neuropsychiatric conditions positions it to potentially impact the treatment landscape significantly.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for addiction and mental health disorders. Headquartered in London and listed on the London Stock Exchange, Solvonis is advancing a pipeline of repurposed and novel compounds targeting neuropsychiatric conditions. The company’s lead programs address Alcohol Use Disorder and Post-Traumatic Stress Disorder, with key assets in various trial phases across Europe, the UK, and the US.
Average Trading Volume: 14,588,439
Technical Sentiment Signal: Sell
Current Market Cap: £7.83M
Learn more about SVNS stock on TipRanks’ Stock Analysis page.